摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl (3R,4S,4aR,5S)-4-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-4a,5-dihydroxy-3-[(4-methoxyphenyl)methoxymethyl]-1-[(2-methylpropan-2-yl)oxycarbonylimino]-4,5,6,7-tetrahydro-3H-pyrrolo[1,2-c]pyrimidine-2-carboxylate | 1185281-47-3

中文名称
——
中文别名
——
英文名称
tert-butyl (3R,4S,4aR,5S)-4-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-4a,5-dihydroxy-3-[(4-methoxyphenyl)methoxymethyl]-1-[(2-methylpropan-2-yl)oxycarbonylimino]-4,5,6,7-tetrahydro-3H-pyrrolo[1,2-c]pyrimidine-2-carboxylate
英文别名
——
tert-butyl (3R,4S,4aR,5S)-4-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-4a,5-dihydroxy-3-[(4-methoxyphenyl)methoxymethyl]-1-[(2-methylpropan-2-yl)oxycarbonylimino]-4,5,6,7-tetrahydro-3H-pyrrolo[1,2-c]pyrimidine-2-carboxylate化学式
CAS
1185281-47-3
化学式
C37H58N6O12
mdl
——
分子量
778.901
InChiKey
YXMGRFDGAMOXOV-LGARNSPHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    55
  • 可旋转键数:
    16
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    219
  • 氢给体数:
    4
  • 氢受体数:
    13

反应信息

  • 作为反应物:
    描述:
    tert-butyl (3R,4S,4aR,5S)-4-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-4a,5-dihydroxy-3-[(4-methoxyphenyl)methoxymethyl]-1-[(2-methylpropan-2-yl)oxycarbonylimino]-4,5,6,7-tetrahydro-3H-pyrrolo[1,2-c]pyrimidine-2-carboxylate2,3-二氯-5,6-二氰基-1,4-苯醌 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 以90%的产率得到tert-butyl (3R,4S,4aR,5S)-4-(2,3-bis(tert-butoxycarbonyl)guanidino)-1-((tert-butoxycarbonyl)imino)-4a,5-dihydroxy-3-(hydroxymethyl)hexahydropyrrolo[1,2-c]pyrimidine-2(1H)-carboxylate
    参考文献:
    名称:
    Total Synthesis of (−)- and (+)-Decarbamoyloxysaxitoxin and (+)-Saxitoxin
    摘要:
    AbstractPlaying the sax: The enantioselective total syntheses of (−)‐ and (+)‐decarbamoyloxysaxitoxin (doSTX) and (+)‐saxitoxin (STX) are reported. A new methodology was developed for the synthesis of STXs, featuring discriminative reduction of the nitro group and NO bond in nitroisoxazolidine.magnified imageEnantioselective total syntheses of (−)‐ and (+)‐decarbamoyloxysaxitoxin (doSTX) and (+)‐saxitoxin (STX) were achieved. The characteristic spiro‐fused cyclic guanidine structure of STX was constructed by oxidation at the C4 position with IBX via an α‐iminium carbonyl intermediate and acid‐promoted cyclization of guanidine at the C5 position. A second‐generation methodology was developed for the synthesis of STX, featuring discriminative reduction of the nitro group and NO bond in nitroisoxazolidine. This approach provides efficient access to the key diamine intermediate for STXs.
    DOI:
    10.1002/asia.200800382
  • 作为产物:
    描述:
    tert-butyl (3R,4S,4aR,5S)-4-amino-1-((tert-butoxycarbonyl)imino)-4a,5-dihydroxy-3-(((4-methoxybenzyl)oxy)methyl)hexahydropyrrolo[1,2-c]pyrimidine-2(1H)-carboxylate 、 N,N'-bis-Boc-S-methyl-isothiourea三乙胺 、 mercury dichloride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 以2.75 g的产率得到tert-butyl (3R,4S,4aR,5S)-4-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-4a,5-dihydroxy-3-[(4-methoxyphenyl)methoxymethyl]-1-[(2-methylpropan-2-yl)oxycarbonylimino]-4,5,6,7-tetrahydro-3H-pyrrolo[1,2-c]pyrimidine-2-carboxylate
    参考文献:
    名称:
    (+)-氨基甲酰基糖原毒素和(+)-Gonyautoxin 3的全合成
    摘要:
    通过使用依赖于邻近基团参与的新颖的,构象控制的胍环化过程,可以轻松构建复杂的毒素(STX)骨架。通过在天然和非天然STX衍生物的合成中使用该方法,证实了该方法的实用性。
    DOI:
    10.1021/ol1006696
点击查看最新优质反应信息

文献信息

  • Total Synthesis of (−)- and (+)-Decarbamoyloxysaxitoxin and (+)-Saxitoxin
    作者:Osamu Iwamoto、Ryoko Shinohara、Kazuo Nagasawa
    DOI:10.1002/asia.200800382
    日期:2009.2.2
    AbstractPlaying the sax: The enantioselective total syntheses of (−)‐ and (+)‐decarbamoyloxysaxitoxin (doSTX) and (+)‐saxitoxin (STX) are reported. A new methodology was developed for the synthesis of STXs, featuring discriminative reduction of the nitro group and NO bond in nitroisoxazolidine.magnified imageEnantioselective total syntheses of (−)‐ and (+)‐decarbamoyloxysaxitoxin (doSTX) and (+)‐saxitoxin (STX) were achieved. The characteristic spiro‐fused cyclic guanidine structure of STX was constructed by oxidation at the C4 position with IBX via an α‐iminium carbonyl intermediate and acid‐promoted cyclization of guanidine at the C5 position. A second‐generation methodology was developed for the synthesis of STX, featuring discriminative reduction of the nitro group and NO bond in nitroisoxazolidine. This approach provides efficient access to the key diamine intermediate for STXs.
  • Total Synthesis of (+)-Decarbamoylsaxitoxin and (+)-Gonyautoxin 3
    作者:Osamu Iwamoto、Kazuo Nagasawa
    DOI:10.1021/ol1006696
    日期:2010.5.7
    Facile construction of the complex saxitoxin (STX) skeleton is carried out by using a novel, conformationally controlled, guanidine cyclization process that relies on the use of neighboring group participation. The utility of this methodology is verified by its employment in syntheses of both natural and unnatural STX derivatives.
    通过使用依赖于邻近基团参与的新颖的,构象控制的胍环化过程,可以轻松构建复杂的毒素(STX)骨架。通过在天然和非天然STX衍生物的合成中使用该方法,证实了该方法的实用性。
查看更多

同类化合物

(2R,3S,5R)-5-(4-氨基-7H-吡咯[2,3-D]嘧啶-7-基-2 -(羟甲基)四氢呋喃-3-醇 鲁索替尼 鲁索利尼杂质C 迪高替尼 诺那吡胺 螺[4.4]壬烷-1-酮,6-氨基-,(5S,6S)- 苯酚,2,4-二氯-5-肼-,单盐酸 苯并呋喃,2,3-二氢-3-(1-甲基乙基)- 聚(氧代-1,2-乙二基),a-甲基-w-[[3,4,4,4-四氟-2-[1,2,2,2-四氟-1-(三氟甲基)乙基]-1,3-二(三氟甲基)-1-丁烯-1-基]氧代]- 维贝格龙 磷酸鲁索替尼 甲基7-(2-甲氧基乙基)-1,3-二甲基-2,4-二羰基-2,3,4,7-四氢-1H-吡咯并[2,3-D]嘧啶-6-羧酸酯 托法替尼杂质28 托法替尼杂质2 托伐替尼杂质T 异丙基2-氨基-4-甲氧基-7h-吡咯并[2,3-d]嘧啶-6-羧酸 巴里替尼杂质5 巴瑞替尼 巴瑞克替尼杂质 巴瑞克替尼中间体3 巴瑞克替尼中间体1 外消旋鲁替替尼-d8 培美酸 吡啶,1-[(2,5-二甲基苯基)甲基]-1,2,3,6-四氢- 吡咯并[1,2-a]嘧啶-3-羧酸 吡咯并[1,2-F]嘧啶-3-甲酸乙酯 吡咯并[1,2-A]嘧啶-6-羧酸 吡咯并[1,2-A]嘧啶-6-甲醛 叔丁基2-氨基-4-氯-5H-吡咯并[3,4-D]嘧啶-6(7H)-羧酸酯 叔丁基-4-氯-2-吗啉代-7H-吡咯并[2,3-D]嘧啶-7-甲酸甲酯 十二烷-1,12-二基二(苯甲基二甲基铵)二氯化 亚乙基,2-氨基-1-(乙酯基<乙氧羰基>)-2-(甲酰基亚氨基)-,(2Z)-(9CI) 二环[2.2.1]庚-5-烯-2-羧酸,丁基酯,(1R,2R,4R)- [4-(1H-吡唑-4-基)-7H-吡咯并[2,3-D]嘧啶-7-基]甲基特戊酸酯 [3-(4-氨基-7H-吡咯并[2,3-d]嘧啶-7-基)环戊基]甲醇 [1-(乙基磺酰基)-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]氮杂环丁烷-3-基]乙腈磷酸盐 S-鲁索替尼 PF-04965842(阿布罗替尼) N-苯基-5H-吡咯并(3,2-d)嘧啶-4-胺 N-苄基-7H-吡咯并[2,3-d]嘧啶-4-胺 N-苄基-5H-吡咯并[3,2-d]嘧啶-4-胺 N-甲基-N-((3S,4S)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺 N-甲基-N-((3R,4R)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺 N-甲基-7h-吡咯并[2,3-d]嘧啶-4-胺 N-甲基-1-((1R,4R)-4-(甲基(7H吡咯[2,3-D]嘧啶-4-基)氨基)环己基)甲磺酰胺富马酸甲酯 N-(5-溴-4-氯-7H-吡咯并[2,3-d]嘧啶-2-基)-2,2-二甲基-丙酰胺 N-(4-甲氧基苯基)-5H-吡咯并(3,2-d)嘧啶-4-胺 N-(4-氯-7H-吡咯并[2,3-D]嘧啶-2-基)-2,2-二甲基丙酰胺 N-(4-氯-5-碘-7H-吡咯[2,3-D]嘧啶-2-基)-2,2-二甲基丙酰胺 N-(4-氯-5-氰基-7H-吡咯并[2,3-d]嘧啶-2-基)-2,2-二甲基丙酰胺